| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
|
| [3] |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识（2021版） [J]. 中华消化外科杂志, 2021, 20(6): 600-616.
|
| [4] |
Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
|
| [5] |
Lai Z, He M, Bu X, et al. Lenvatinib, Toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase Ⅱ trial[J]. Eur J Cancer, 2022, 174: 68-77.
|
| [6] |
He M, Ming S, Lai Z, Li Q. A phase Ⅱ trial of Lenvatinib plus Toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study)[J]. J Clin Oncol, 2021, 39 (suppl 15): 4083.
|
| [7] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
|
| [8] |
Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
|
| [9] |
Hu Z, Yang Z, Wang J, et al. Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus[J]. Front Pharmacol, 2023, 14: 1223632.
|
| [10] |
Finn RS, Ryoo BY, Hsu CH, et al. Results from the MORPHEUS-liver study: phase Ⅰb/Ⅱ randomized evaluation of Tiragolumab (tira) in combination with Atezolizumab (atezo) and Bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2023, suppl 16: abstr 4010.
|
| [11] |
Dawson L, Winter K, Knox J, et al. NRG/RTOG 1112: randomized phase Ⅲ study of Sorafenib vs. Stereotactic body radiation therapy (SBRT) followed by Sorafenib in hepatocellular carcinoma (HCC) (NCT01730937)[J]. Int J Radiat Oncol Biol Phys, 2022, 114(5): 1057.
|
| [12] |
Qin SK. First-line Lenvatinib plus Pembrolizumab for advanced heptocellular carcinoma: LEAP-002 Asian subgroup analysis[G]. JSMO, 2023.
|
| [13] |
Sun T, Ren Y, Sun B, et al. The feasibility of TACE combined with TKIs plus PD-1 antibody for advanced HCC[J]. J Hepatocell Carcinoma, 2023, 10: 447-457.
|
| [14] |
Yu B, Zhang N, Feng Y, et al. Tyrosine kinase inhibitors plus Anti-PD-1 antibodies with hepatic arterial infusion chemotherapy or transarterial chemoembolization for unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2023, 10: 1735-1748.
|
| [15] |
Brozzetti S, D’Alterio C, Bini S, et al. Surgical resection is superior to TACE in the treatment of HCC in a well selected cohort of BCLC-B elderly patients-a retrospective observational study[J]. Cancers (Basel), 2022, 14(18): 4422.
|
| [16] |
Liu J, Yan S, Zhang G, et al. A retrospective study of transarterial chemoembolization (TACE) combined with Lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma[J]. Oncol Lett, 2023, 26(6): 507.
|
| [17] |
Lin LW, Ke K, Yan LY, et al. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization[J]. Front Oncol, 2023, 13: 1178428.
|
| [18] |
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
|
| [19] |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a Bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
|
| [20] |
Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠ b study of Lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
|